15 research outputs found
Chelator-facilitated removal of iron from transferrin: Relevance to combined chelation therapy
Current iron chelation therapy consists primarily of DFO (desferrioxamine),
which has to be administered via intravenous infusion,
together with deferiprone and deferasirox, which are orally-active
chelators. These chelators, although effective at decreasing the
iron load, are associated with a number of side effects. Grady
suggested that the combined administration of a smaller bidentate
chelator and a larger hexadentate chelator, such as DFO, would
result in greater iron removal than either chelator alone [Grady,
Bardoukas and Giardina (1998) Blood 92, 16b]. This in turn
could lead to a decrease in the chelator dose required. To test
this hypothesis, the rate of iron transfer from a range of bidentate
HPO (hydroxypyridin-4-one) chelators to DFO was monitored.
Spectroscopic methods were utilized to monitor the decrease in
the concentration of the Fe–HPO complex. Having established
that the shuttling of iron from the bidentate chelator to DFO
does occur under clinically relevant concentrations of chelator,
studies were undertaken to evaluate whether this mechanism of
transfer would apply to iron removal from transferrin. Again, the
simultaneous presence of both a bidentate chelator and DFO was
found to enhance the rate of iron chelation from transferrin at
clinically relevant chelator levels. Deferiprone was found to be
particularly effective at ‘shuttling’ iron from transferrin to DFO,
probably as a result of its small size and relative low affinity for
iron compared with other analogous HPO chelators
Absence of evidence of Xenotropic Murine Leukemia Virus-related virus infection in persons with Chronic Fatigue Syndrome and healthy controls in the United States
<p>Abstract</p> <p>Background</p> <p>XMRV, a xenotropic murine leukemia virus (MuLV)-related virus, was recently identified by PCR testing in 67% of persons with chronic fatigue syndrome (CFS) and in 3.7% of healthy persons from the United States. To investigate the association of XMRV with CFS we tested blood specimens from 51 persons with CFS and 56 healthy persons from the US for evidence of XMRV infection by using serologic and molecular assays. Blinded PCR and serologic testing were performed at the US Centers for Disease Control and Prevention (CDC) and at two additional laboratories.</p> <p>Results</p> <p>Archived blood specimens were tested from persons with CFS defined by the 1994 international research case definition and matched healthy controls from Wichita, Kansas and metropolitan, urban, and rural Georgia populations. Serologic testing at CDC utilized a Western blot (WB) assay that showed excellent sensitivity to MuLV and XMRV polyclonal or monoclonal antibodies, and no reactivity on sera from 121 US blood donors or 26 HTLV-and HIV-infected sera. Plasma from 51 CFS cases and plasma from 53 controls were all WB negative. Additional blinded screening of the 51 cases and 53 controls at the Robert Koch Institute using an ELISA employing recombinant Gag and Env XMRV proteins identified weak seroreactivity in one CFS case and a healthy control, which was not confirmed by immunofluorescence. PCR testing at CDC employed a <it>gag </it>and a <it>pol </it>nested PCR assay with a detection threshold of 10 copies in 1 ug of human DNA. DNA specimens from 50 CFS patients and 56 controls and 41 US blood donors were all PCR-negative. Blinded testing by a second nested gag PCR assay at the Blood Systems Research Institute was also negative for DNA specimens from the 50 CFS cases and 56 controls.</p> <p>Conclusions</p> <p>We did not find any evidence of infection with XMRV in our U.S. study population of CFS patients or healthy controls by using multiple molecular and serologic assays. These data do not support an association of XMRV with CFS.</p
Chronic fatigue syndrome: identification of transcription factor (TFs) associated with gene expression for drug signature prediction
Acupuncture and Moxibustion have Different Effects on Fatigue by Regulating the Autonomic Nervous System: A Pilot Controlled Clinical Trial
Combined chelation of lead (II) by deferasirox and deferiprone in rats as biological model
Immunophenotyping in post-giardiasis functional gastrointestinal disease and chronic fatigue syndrome
<p>Abstract</p> <p>Background</p> <p>A <it>Giardia</it> outbreak was associated with development of post-infectious functional gastrointestinal disorders (PI-FGID) and chronic fatigue syndrome (PI-CFS). Markers of immune dysfunction have given conflicting results in CFS and FGID patient populations. The aim of this study was to evaluate a wide selection of markers of immune dysfunction in these two co-occurring post-infectious syndromes.</p> <p>Methods</p> <p>48 patients, reporting chronic fatigue in a questionnaire study, were clinically evaluated five years after the outbreak and grouped according to Fukuda criteria for CFS (n=19) and idiopathic chronic fatigue (n=5) and Rome II criteria for FGIDs (n=54). 22 <it>Giardia</it> exposed non-fatigued individuals and 10 healthy unexposed individuals were recruited as controls. Peripheral blood lymphocyte subsets were analyzed by flow cytometry.</p> <p>Results</p> <p>In peripheral blood we found significantly higher CD8 T-cell levels in PI-FGID, and significantly lower NK-cell levels in PI-CFS patients. Severity of abdominal and fatigue symptoms correlated negatively with NK-cell levels. A tendency towards lower T-cell CD26 expression in FGID was seen.</p> <p>Conclusion</p> <p>Patients with PI-CFS and/or PI-FGID 5 years after <it>Giardia lamblia</it> infection showed alterations in NK-cell and CD8-cell populations suggesting a possible immunological abnormality in these conditions. We found no significant changes in other markers examined in this well-defined group of PI-CFS and PI-FGID elicited by a gastrointestinal infection. Controlling for co-morbid conditions is important in evaluation of CFS-biomarkers.</p